Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
634.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 1.00 (0.159%)
Market Cap: £767.37m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

2023 AGM Notification

5 May 2023 07:00

RNS Number : 4997Y
Oxford Biomedica PLC
05 May 2023
 

Oxford Biomedica PLC

2023 AGM Notification

London, UK - 5 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "the Company" or "the Group"), a quality and innovation-led viral vector CDMO, gives notice that the Notice of Annual General Meeting ("AGM") together with a copy of the 2022 Annual report and accounts are being sent to shareholders today. These documents are available on the "Investors" section of the Group's website at www.oxb.com.

In accordance with Listing rule 9.6.1, a copy of the Notice of AGM has been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.The Company intends to hold its AGM on Friday 23 June 2023 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m.

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

Notes for editors

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUSAKROUUVRAR
Date   Source Headline
10th Aug 201811:36 amRNSDirector Dealings / Market Share Sale and Purchase
8th Aug 20182:45 pmRNSShare Options and LTIPs Granted
6th Aug 20187:02 amRNSPartnership for Cystic Fibrosis Gene Therapy
1st Aug 20189:53 amRNSTotal Voting Rights
23rd Jul 201812:54 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 201810:25 amRNSDirectorate Change
2nd Jul 20189:47 amRNSTotal Voting Rights
29th Jun 20181:37 pmRNSKymriah receives positive CHMP opinion
25th Jun 20185:19 pmRNSHoldings in Company
22nd Jun 201812:05 pmRNSConfirmation of change of Auditor
22nd Jun 201812:03 pmRNSDirector Dealings / Market Share Purchase
21st Jun 20185:52 pmRNSHoldings in Company
14th Jun 20189:51 amEQSHardman & Co Research: Oxford BioMedica (OXB): Gene-therapy for Parkinson's: clinical progression
6th Jun 20187:00 amRNSOXB and Axovant Sciences Licence Agreement
4th Jun 20186:08 pmRNSDirectorate Change
1st Jun 20189:24 amRNSBlock Listing Return
1st Jun 20189:19 amRNSTotal Voting Rights
30th May 20184:23 pmRNSHoldings in Company
29th May 20181:21 pmRNSResult of General Meeting
29th May 20181:21 pmRNSResult of AGM
23rd May 20181:40 pmRNSDirector Dealings / Market Share Purchase
4th May 20187:00 amRNSProposed Share Capital Consolidation
2nd May 20187:00 amRNSKymriah receives FDA approval for DLBCL
1st May 20189:37 amRNSTotal Voting Rights
26th Apr 20183:33 pmRNSHolding(s) in Company
26th Apr 20187:30 amRNS2017 Annual Report and Accounts & AGM Notification
23rd Apr 201811:46 amRNSDirector Dealings / Market Share Purchase
11th Apr 20182:11 pmRNSDirector Dealings / Market Share Purchase
9th Apr 20185:39 pmRNSDirector/PDMR Shareholding
9th Apr 201810:47 amRNSDirector/PDMR Shareholding
5th Apr 201812:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20189:45 amRNSTotal Voting Rights
22nd Mar 201811:05 amRNSDirector/PDMR Shareholding
20th Mar 20187:15 amRNSHardman & Co Res: Supply to meet demand
15th Mar 20187:01 amRNSBoard Change
15th Mar 20187:01 amRNSPreliminary Results
9th Mar 20186:41 pmRNSResult of Placing
9th Mar 20183:42 pmRNSPROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
9th Mar 20183:17 pmRNSPROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
1st Mar 20189:33 amRNSTotal Voting Rights
28th Feb 20187:15 amRNSHardman & Co Res: BIVV deal establishes structure
23rd Feb 20182:03 pmRNSDirector/PDMR Shareholding
20th Feb 20182:12 pmRNSHoldings in Company
15th Feb 20187:00 amRNSBioverativ Collaboration and Licence Agreement
1st Feb 201811:28 amRNSTotal Voting Rights
23rd Jan 20189:45 amRNS£3 million Innovate UK grant
23rd Jan 20189:30 amRNSDirector Dealings / Market Share Purchase
17th Jan 20187:00 amRNSKymriah receives Priority Review for adult DLBCL
9th Jan 20189:54 amRNSBLOCK LISTING RETURN
9th Jan 20189:54 amRNSBLOCK LISTING RETURN

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.